Immunodiagnostic Systems Hldgs PLC Launch of IDS-iSYS Total Testosterone assay (8864M)
19 October 2016 - 5:00PM
UK Regulatory
TIDMIDH
RNS Number : 8864M
Immunodiagnostic Systems Hldgs PLC
19 October 2016
Immunodiagnostic Systems Holdings plc.
19 October 2016
Launch of IDS-iSYS Total Testosterone assay - new assay in the
IDS fertility portfolio
Immunodiagnostic Systems Holdings plc (IDS), a specialist
producer of manual and automated diagnostic testing kits and
instruments for the clinical market, has launched the IDS-iSYS
Total Testosterone assay in the European market. This is a fully
automated CLIA assay for use with serum and plasma samples on the
IDS-iSYS Automated System.
The launch of the IDS-iSYS Total Testosterone assay is the
second product released as part of the emerging fertility (steroid
hormones) portfolio following the launch of the IDS-iSYS 17-OH
Progesterone assay in May 2016.
The IDS-iSYS Total Testosterone assay quantitatively measures a
patient's Testosterone level and offers clinicians an easy,
non-invasive way to diagnose and treat disorders involving the male
sex hormones (androgens).
The global market for testosterone tests has been valued at
around $110 million per year.
For further information:
Immunodiagnostic Systems Holdings plc Tel: +44 (0) 191 519 0660
Patricio Lacalle, Chief Executive Officer
Paul Martin, Group Finance Director
Peel Hunt LLP Tel: +44 (0) 20 7418 8900
James Steel
Oliver Jackson
This information is provided by RNS
The company news service from the London Stock Exchange
END
PRLFFWFWAFMSEES
(END) Dow Jones Newswires
October 19, 2016 02:00 ET (06:00 GMT)
Immunodiagnostic Systems (LSE:IDH)
Historical Stock Chart
From Apr 2024 to May 2024
Immunodiagnostic Systems (LSE:IDH)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Immunodiagnostic Systems Holdings Plc (London Stock Exchange): 0 recent articles
More Immuno. Sys News Articles